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ABSTRACT 
Acinar cell carcinomas (ACCs) of the pancreas are a heterogeneous group of neoplasms 
showing a wide spectrum of morphological features including acinar, solid, glandular, and 
trabecular architecture. In addition, uncommon cytological aspects have recently been 
described and include oncocytic, spindle, clear, and pleomorphic cell types. This wide 
histological spectrum represents a challenge in the diagnostic task for pathologists. 
Molecular mechanisms involved in the onset and progression of ACCs are not completely 
known, but, in general, they differ from those observed in ductal adenocarcinomas or 
neuroendocrine neoplasms of the pancreas and frequently include alterations in the APC/β-
catenin pathway. In the present paper, we describe a new variant of ACC showing thyroid-
like follicular features and CTNNB1 mutation. This phenotype needs to be included in the 
spectrum of morphological presentation of ACC. 
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Introduction 
Pancreatic acinar cell carcinomas (ACCs) may show different architectural patterns of growth 
including acinar, solid, glandular, and trabecular structures. In addition, other uncommon 
cytological features have recently been described and include oncocytic, spindle, clear, and 
pleomorphic cell types and this wide histological spectrum gives rise to difficulties in the 
differential diagnosis with other pancreatic neoplasms [1-4]. In such instances, 
immunohistochemistry is an essential tool to demonstrate acinar-specific products including 
trypsin, chymotrypsin, amylase, lipase, and carboxyl ester hydrolase [4], the last also 
detected with the anti-BCL10 monoclonal antibody [5]. It is worth noting that antibodies 
directed against these different markers differ in terms of sensitivity [2, 5, 6]. Anti-lipase and 
anti-amylase antibodies detect a low percentage of cases (<30% and <10%, respectively) [2], 
while anti-chymotrypsin antibody about 70% of ACCs [6]. Anti-trypsin and anti-BCL10 
antibodies show the best sensitivity detecting 96% and 85% of cases, respectively [2], but 
their simultaneous use identifies about 100% of cases [2, 5]. 
In the present paper, we describe the clinico-pathologic and molecular features of an 
ACC showing a thyroid-like architectural pattern, which has never been previously described. 
 
Case report 
A previously healthy 51-year-old man presented with back pain and weight loss of 10 kg over 
the last year. Contrast enhanced abdominal CT scan and MRI showed a well-circumscribed 
mass, located in the uncinate process of the pancreas. Pancreatic endoscopic ultrasound fine 
needle aspiration was performed and a diagnosis of adenocarcinoma, not otherwise 
specified (NOS), was rendered. The patient underwent pancreaticoduodenectomy. Four 
 
 
4 
 
months later, chemotherapy with gemcitabine and capecitabine was started and 33 months 
after surgery, the patient was alive free of disease. 
 
Materials and Methods 
Immunohistochemistry was performed on a Ventana Benchmark XT autostainer (Ventana 
Medical System, Tucson, AZ, USA) using the antibodies listed in Table 1. 
 A representative FFPE tissue block was used for gene mutation, and rearrangement 
analysis. For mutation analysis by Next Generation Sequencing (NGS), an amplicon-based 
DNA library was prepared using a customized primer panel targeting 218 hotspot regions of 
52 cancer genes (custom Ion AmpliSeq panel, Ion Torrent, Thermo Fisher Scientific, 
Waltham, MA, USA), and subsequently sequenced on an Ion Personal Genome Machine 
(PGM, Ion Torrent). For rearrangement analysis, the Archer FusionPlex Lung Kit (ArcherDX, 
Boulder, CO, USA) was applied to identify fusions involving 14 genes, including BRAF. This 
NGS technology allows the detection of chimeric transcripts even without prior knowledge 
of fusion partners or breakpoints. Starting from 200 ng RNA, the library was prepared 
according to manufacturer’s instructions and sequenced on a MiSeq instrument (Illumina, 
San Diego, CA, USA). Furthermore, for RET and PPARγ gene rearrangements, interphase 
fluorescence in situ hybridization (FISH) assays were performed on 4μm-thick sections using 
break-apart probes (ZytoLight SPEC RET Dual Color Break Apart Probe, ZytoVision, 
Bremerhaven, Germany; and Kreatech PPARG (3p25) Break FISH probe, Leica Biosystems, 
Nussloch, Germany), according to standard protocols. 
 
Results 
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Fine needle aspiration of the mass yielded highly cellular smears comprising cohesive sheets 
and clusters of monomorphic cells, occasionally demonstrating glandular architecture. 
Amorphous eosinophilic colloid-like material was visible in the background or inside 
glandular lumens (Fig. 1A). Tumor cells were intermediate in size, polygonal, with finely 
granular cytoplasm. Nuclei were mostly round, regular, with smooth contour, prominent 
nucleolus and granular chromatin. On cell block, tumor cells were arranged in regular 
glandular structures, whose lumens contained a PAS-positive amorphous material (Fig. 1B). 
Neoplastic cells showed diffuse expression of CK7 and CK19. Chromogranin A (Fig. 1C) and 
synaptophysin were focally positive. BCL10 and trypsin were negative in tumor cells, 
although the former was positive in the amorphous material (Fig. 1D). 
 At gross examination, the tumor was well-circumscribed measuring 4.3 x 4.0 x 3.2cm 
and the cut surface was white-to-yellow and had a lobulated appearance. 
 Histologically, the tumor displayed follicular structures of varying sizes filled with 
amorphous, eosinophilic, PAS-positive colloid-like material, strongly resembling thyroid 
tissue (Fig. 2A). Intratumor fibrous stroma was scant and extensive necrosis was lacking. At 
higher magnification, follicles were lined by cuboidal to columnar cells containing a 
moderate amount of finely granular eosinophilic cytoplasm. The nuclei were round to oval, 
with a granular chromatin and a single nucleolus (Fig. 2B); they displayed focal chromatin 
clearing and nuclear grooving. Perineural and vascular invasion were observed. Two out 35 
peripancreatic lymph nodes were metastatic. Tumor cells were immunoreactive for 
CKAE1/AE3, CK7, CK19, EMA, CD10, α-methylacyl CoA racemase, hMLH1, hMSH2, hMSH6, 
and hPMS2. The immunoreactivity for trypsin and BCL10 was heterogeneous in the tumor. 
Indeed, tumor cells showed a patchy but intense positivity for trypsin and BCL10: about 40% 
were positive for BCL10 and 60% for trypsin. Interestingly, in areas where neoplastic cells 
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were negative, trypsin and BCL10 stained the PAS-positive colloid-like material (Fig. 2C-F). 
Synaptophysin (Fig. 2G) and chromogranin A were expressed in scattered cells (<30% of 
tumor cells), which sometimes were also positive for trypsin. TTF1, thyroglobulin, PAX8, 
CDX2, lipase, amylase, PSA, CK20, insulin, glucagon, somatostatin, and α-inhibin were 
negative. β-catenin showed preserved membrane positivity, but an additional nuclear 
accumulation of the protein was observed in several tumor cells, with variable intensity (Fig. 
2H). The Ki67 proliferative index was counted at 30%. 
 NGS mutation analysis yielded a mean coverage of 1504X and revealed two missense 
mutations: a c.95A>T (p.D32V) mutation in exon 3 of CTNNB1 (allele frequency of 83%) and a 
c.740A>G (p.K247R) mutation in exon 4 of ABL1 (allele frequency of 9%). The other genomic 
regions investigated, including the hotspot regions of KRAS, NRAS, HRAS, BRAF and TP53 
genes, did not show any detectable mutation. Copy number variation (CNV) analysis based 
on local reads coverage obtained from NGS data showed low level gains at chromosomal 
regions 1q, 3, 5q, 7p, 10, 13q, and of a more significant copy number gain of 20q (around 6 
copies per cell). 
 No fusion transcript was detected involving any of the 14 genes screened by NGS, 
including the BRAF fusions previously described in pancreatic ACCs [7]. 
 FISH assays demonstrated a copy number gain of RET (10q11; 3 to 6 copies per 
nucleus) and PPARγ  (3p25; 2 to 4 copies), but did not evidence any rearrangement of these 
genes. 
 
Discussion 
 Pancreatic ACCs are a heterogeneous group of neoplasms showing a wide spectrum 
of morphological features including acinar, solid, glandular, and trabecular architectural 
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patterns. In addition, other uncommon variants have been described and include oncocytic, 
spindle, clear, and pleomorphic cell types [2, 4]. 
We describe for the first time an ACC with striking histological features resembling a 
well-differentiated follicular neoplasm of the thyroid. This new subtype represents a 
challenging entity due to the peculiar morphological features and to the patchy expression 
of acinar cell markers. The latter characteristic may represent a major diagnostic pitfall, 
especially on cytological examination. Indeed, in our cytology specimens both trypsin and 
BCL10 were positive in the colloid-like material, but negative in tumor cells, leading us to 
miss the preoperative diagnosis of ACC. The lack of cytoplasmic immunoreactivity for both 
acinar cell markers was also observed in several areas of the tumor at histological 
examination. Indeed, their cytoplasmic immunoreactivity was mainly absent in areas where 
the intraluminal colloid-like material was strongly positive for both BCL10 and trypsin. This 
suggests that the enzymes-containing colloid-like material is actively secreted by tumor cells, 
which discharge their enzymes content, resulting, in turn, in the lack of cytoplasmic 
immunoreactivity. The secreted material accumulated within the lumens determined their 
dilatation, conferring a “thyroid-like” appearance. 
The peculiar morphological features of the present case raised the possibility of a 
metastasis from a thyroid carcinoma, which was excluded as the tumor was negative for 
thyroglobulin and TTF-1. In addition, the patient did not have a previous history of thyroid 
cancer and thyroid lesions were not detected at radiological investigation. Cases of primary 
renal and breast carcinomas, liver cholangiocarcinoma, and hepatic neuroendocrine 
neoplasm morphologically resembling thyroid follicular neoplasms have been reported in 
the literature and in all of them the neoplastic cells were negative for thyroid markers [8-11]. 
 
 
8 
 
The prognostic meaning of “thyroid-like” features in these cancers is not clear, since follow-
up data are limited. 
Another diagnostic issue was represented by the focal expression of neuroendocrine 
markers that may suggest the diagnosis of neuroendocrine neoplasm, especially in the 
cytology specimen. Scattered neuroendocrine cells are frequently observed in ACCs [2] and 
only when they represent at least 30% of the tumor tissue, the neoplasm is defined as mixed 
acinar-neuroendocrine carcinoma, a tumor type that belongs to the large group of mixed 
neuroendocrine-non neuroendocrine neoplasms (MiNENs) [12, 13]. 
The molecular profile of the present case included a c.95A>T (p.D32V) mutation in 
exon 3 of CTNNB1, a c.740A>G (p.K247R) mutation in exon 4 of ABL1, and a copy number 
gain of 20q. The other genes investigated, including KRAS, NRAS, HRAS, BRAF and TP53 did 
not show any mutation. The lack of RAS and BRAF mutations is in line with literature data, 
which indicate that KRAS mutations are practically absent in ACCs and that BRAF mutations 
are exceedingly rare [4]. Furthermore, the presence of recurrent BRAF fusions has recently 
been described in over 20% of pancreatic acinar-type neoplasms [7]. In our analysis did not 
found such BRAF alterations nor other fusion genes. Thanks to the peculiar NGS technology 
used to search for fusion transcripts (i.e., Anchored Multiplex PCR or AMP), rearrangements 
involving BRAF with any other partner gene would have been detected, even if not 
previously reported.  Regarding TP53, mutations in this gene have been described in about 
12% of ACCs [4] and, when associated with loss of the other allele, are associated with worse 
survival [14]. Although alterations in the APC/β-catenin pathway are relatively frequent in 
ACCs, mutations in the CTNNB1 gene have been described in only 7% of cases [15]. In the 
present case we found an activating mutation in exon 3 of CTNNB1: similarly to other 
alterations affecting the N-terminal region of β-catenin, this D32V substitution appears to 
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prevent full phosphorylation of the protein, thereby leading to its abnormal stabilization and 
nuclear accumulation [16], as observed in this case with immunohistochemistry. Nuclear 
expression of β-catenin has been described in SPN, which, however, are negative for BCL10 
and trypsin. The mutation detected in ABL1 has been reported in approximately 0.5% of 
healthy European population (ExAC database) and is probably of little functional interest. 
Moreover, the copy number gain observed at 20q is consistent with what has been reported 
in ACC in previous studies [17, 18]. In line with the pancreatic origin of the cancer, FISH 
analysis did not show rearrangements of RET and PPARγ genes, which are genes involved in 
the pathogenesis of thyroid carcinomas. 
In conclusion, a new variant of ACC showing thyroid-like follicular features is 
described and it should be added to spectrum of morphological variability of ACC. 
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Figure legends 
Figure 1. Fine-needle aspiration cytology of the pancreatic tumor was hypercellular with 
abundant 3D clusters. Colloid-like material was visible in the background (arrow) (A). 
Sections obtained from the cell block showed well-formed micro and macrofollicular-like 
structures containing amorphous colloid-like material, which was also observed in the 
background. Tumor cells were of intermediate-size, polygonal, with finely granular 
cytoplasm. Nuclei were mostly round, regular, with smooth contour, prominent nucleolus 
and granular chromatin, with a mild degree of pleomorphism (B). Chromogranin A was 
focally intensely positive (C), and BCL10 was positive in colloid-like material, but not in tumor 
cells (D). 
Figure 2. At low magnification, the tumor was characterized by follicular-like structures of 
varying sizes filled with amorphous, eosinophilic, colloid-like material strongly resembling 
thyroid tissue (A). At higher magnification follicle-like structures were lined by monotonous 
and regular cuboidal to columnar cells containing a moderate amount of finely granular 
eosinophilic cytoplasm. Their nuclei were round to oval, with a granular chromatin and a 
single nucleolus (B). In large areas of the tumor BCL10 was only positive in colloid-like 
material as observed in cytologic specimens (C). However, in other areas several cells 
showed cytoplasmic BCL10 immunoreactivity (D). Similar findings were observed for trypsin 
(E and F). Synaptophysin (G) was positive in less than 30% of cells and β-catenin showed 
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preserved membrane positivity, but an additional nuclear accumulation of the protein was 
observed in a significant number of tumor cells (H). 


Table 1. Antibodies and antisera used. 
Antibodies/antisera P/M(Clone) Dilution Source 
    
Trypsin M(MAB1482) 1:100 Chemicon-Millipore International Inc., Temecula, CA, USA 
BCL10 M(331.3) 1:300 Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA 
Amylase M(6103) 1:2500 BioGenex Laboratories, San Ramon, CA, USA 
Lipase M(MAB1453) 1:1000 Chemicon-Millipore International Inc. 
Cytokeratin M(AE1/AE3) 1:5 Novocastra, Benton, UK 
Cytokeratin 7 M(OV-TL 12/30) 1:200 Dako, Carpinteria, CA, USA 
Cytokeratin 19 M(RCK108) 1:50 Dako  
Cytokeratin 20 M(IT-Ks 20.8) 1:80 Progen Biotechnik, Heidelberg, Germany 
EMA M(E29) 1:100 Dako 
Synaptophysin M(27G12) 1:100 Novocastra 
Chromogranin A P 1:1000 Dako 
Glucagon P 1:500 Cell Marque, Rocklin, CA, USA 
Insulin P 1:200 Dako 
Gastrin P 1:1000 Dako 
Somatostatin P 1:3000 Dako 
CD10 M(56C6) 1:50 Novocastra 
PAX8 P 1:200 Proteintech, Rosemont, IL, USA 
Thyroglobulin M(1D4) 1:600 Novocastra 
TTF-1 M(8G7G3/1) 1:30 Invitrogen, Carlsbad, CA, USA 
CDX2 M(CDX2-88) 1:40 BioGenex 
α-inhibin M(R1) 1:10 Bio-Rad, Hercules, CA, USA 
α-methylacyl CoA racemase M(13H4) 1:1 Biologo, Kronshagen, Germany 
PSA P 1:1000 Dako 
β-catenin M(14) 1:1 Ventana/Roche, Tucson, AZ, USA 
hMLH1 M(M1) 1:1 Ventana/Roche 
hMSH2 M(G219-1129) 1:1 Ventana/Roche 
hMSH6 M(44) 1:1 Ventana/Roche 
hPMS2 M(EPR3947) 1:1 Ventana/Roche 
Ki67 M(MIB1) 1:50 Dako 
    
P/M: polyclonal/monoclonal; EMA: epithelial membrane antigen; PSA: prostatic specific antigen. 
 
